Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Braz. j. med. biol. res ; 47(8): 646-654, 08/2014. tab, graf
Article Dans Anglais | LILACS | ID: lil-716273

Résumé

The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood. In this study, we investigated local changes in cardiac aldosterone and its synthase in rats with ISO-induced CHF, and evaluated the effects of treatment with recombinant human brain natriuretic peptide (rhBNP). Sprague-Dawley rats were divided into 4 different groups. Fifty rats received subcutaneous ISO injections to induce CHF and the control group (n=10) received equal volumes of saline. After establishing the rat model, 9 CHF rats received no further treatment, rats in the low-dose group (n=8) received 22.5 μg/kg rhBNP and those in the high-dose group (n=8) received 45 μg/kg rhBNP daily for 1 month. Cardiac function was assessed by echocardiographic and hemodynamic analysis. Collagen volume fraction (CVF) was determined. Plasma and myocardial aldosterone concentrations were determined using radioimmunoassay. Myocardial aldosterone synthase (CYP11B2) was detected by quantitative real-time PCR. Cardiac function was significantly lower in the CHF group than in the control group (P<0.01), whereas CVF, plasma and myocardial aldosterone, and CYP11B2 transcription were significantly higher than in the control group (P<0.05). Low and high doses of rhBNP significantly improved hemodynamics (P<0.01) and cardiac function (P<0.05) and reduced CVF, plasma and myocardial aldosterone, and CYP11B2 transcription (P<0.05). There were no significant differences between the rhBNP dose groups (P>0.05). Elevated cardiac aldosterone and upregulation of aldosterone synthase expression were detected in rats with ISO-induced CHF. Administration of rhBNP improved hemodynamics and ventricular remodeling and reduced myocardial fibrosis, possibly by downregulating CYP11B2 transcription and reducing myocardial aldosterone synthesis.


Sujets)
Animaux , Humains , Mâle , Aldostérone/sang , /métabolisme , Défaillance cardiaque/traitement médicamenteux , Myocarde/métabolisme , Natriurétiques/usage thérapeutique , Peptide natriurétique cérébral/usage thérapeutique , Aldostérone/génétique , Cardiotoniques , Maladie chronique , Collagène/analyse , Modèles animaux de maladie humaine , Échocardiographie , Fibrose/étiologie , Défaillance cardiaque/induit chimiquement , Défaillance cardiaque/métabolisme , Hémodynamique/effets des médicaments et des substances chimiques , Isoprénaline , Soins de longue durée , Myocarde/anatomopathologie , Natriurétiques/administration et posologie , Peptide natriurétique cérébral/administration et posologie , Rat Sprague-Dawley , Réaction de polymérisation en chaine en temps réel , Protéines recombinantes/usage thérapeutique , Transcription génétique/effets des médicaments et des substances chimiques , Remodelage ventriculaire/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
Détails de la recherche